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Key points box: 
- In the patients with non cirrhotic portal hypertension variceal progression is more rapid than 
in cirrhotic patients.  
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- In the patients with non cirrhotic portal hypertension variceal bleeding is more frequent than 
in cirrhotic patients.  
- The patients with INCPH are particularly prompt to develop a portal vein thrombosis  
- In patients with non cirrhotic portal hypertension the use of the same strategies used for 
cirrhotic patients with portal hypertension may not be correct, both in terms of follow-up 
and treatments 
 
ABSTRACT 
Background. The knowledge of natural history of patients with portal hypertension (PH) not due to 
cirrhosis is less well known than that of cirrhotic patients. 
Aim. To describe the clinical presentation and the outcomes of 89 patients with non-cirrhotic PH 
(25 with non-cirrhotic portal hypertension, INCPH, and 64 with chronic portal vein thrombosis, 
PVT) in comparison with 77 patients with Child A cirrhosis.  
Methods. The patients were submitted to a standardized clinical, laboratory, ultrasonographic and 
endoscopic follow-up. Variceal progression, incidence of variceal bleeding, portal vein thrombosis, 
ascites and survival were recorded.  
Results. At presentation, the prevalence of varices, variceal bleeding and ascites was similar in the 
3 groups. During follow-up, the rate of progression to varices at risk of bleeding (p<0.0001) and the 
incidence of first variceal bleeding (p=0.02) were significantly higher in non-cirrhotic then in 
cirrhotic patients. A PVT developed in 32% of INCPH patients and in 18% of cirrhotics (p=0.02).  
Conclusions. In the patients with non–cirrhotic PH variceal progression is more rapid and bleeding 
more frequent than in cirrhotics.  Patients with INCPH are particularly prompt to develop PVT. This 
observational study suggests that the management of patients with non-cirrhotic PH should take 
into consideration the natural history of portal hypertension in these patients and cannot be simply 
derived by the observation of cirrhotic patients. 
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Abbreviations: NCPH: non-cirrhotic portal hypertension; INCPH: idiopathic non-cirrhotic portal 
hypertension; PVT: portal vein thrombosis;  
 
Keywords: idiopathic non-cirrhotic portal hypertension, chronic portal vein thrombosis, portal 
hypertension, natural history 
 
 
INTRODUCTION 
 In the Western world, liver cirrhosis is the most common cause of portal hypertension. 
However, with the development of imaging technologies, cases of portal hypertension due to 
chronic portal vein thrombosis (PVT) have been increasingly recognized. In a minority of patients, 
portal hypertension may also develop in the absence of both cirrhosis and chronic PVT. In these 
patients the cause of portal hypertension is intrahepatic and histological features involve a wide 
spectrum of nonspecific changes ranging from sinusoidal dilatation, phlebosclerosis and portal 
fibrosis to nodular regenerative hyperplasia 1 in the absence of the histological features of cirrhosis. 
Recently, the clinical aspects of this infrequent disease have been described and the term idiopathic 
non cirrhotic portal hypertension (INCPH) has been proposed to facilitate cooperative studies 2. In 
the west, the knowledge on the natural history and clinical outcomes of portal hypertension not due 
to cirrhosis, is based on studies on a limited number of patients either for chronic PVT 3-7 and 
INCPH 8-14. Because of these limited information, current recommendations for the management of 
these patients suggest to apply the same guidelines on the treatment of portal hypertension of 
cirrhotic patients 15-16.  
The aim of the present study was to describe the disease presentation and the incidence of 
the principal clinical outcomes (variceal progression, incidence of variceal bleeding, portal vein 
thrombosis and ascites as well as survival) which occurred in a group of 89 patients with portal 
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hypertension not due to cirrhosis, in comparison to 77 patients with compensated cirrhosis (Child 
Pugh A) at the first observation.  
 
PATIENTS AND METHODS 
  89 patients with non cirrhotic portal hypertension observed between 1993 and 2016 were 
included in the study immediately after diagnosis. Sixty-four were affected by chronic portal vein 
thrombosis (PVT) and 25 by idiopathic non-cirrhotic portal hypertension (INCPH). Portal 
hypertension was diagnosed on the presence of splenomegaly and oesophageal varices or other 
portal-systemic collaterals. Portal hypertension was attributed to chronic PVT when imaging 
techniques (doppler ultrasound and contrast-enhanced CT-scan) showed the presence of portal 
cavernoma, defined as the development of a network of tortuous collateral vessels bypassing the 
obstructive area at hepatic hilum. Neoplastic portal vein obstruction was excluded on the basis of 
imaging studies and evidence of no neoplastic disease. Cirrhosis was excluded on the absence of 
causes of chronic liver diseases, normal liver protein synthetic capacity, absence of advanced 
fibrosis on liver elastometry and liver biopsy in selected cases. In addition, liver biopsy was also 
performed in 13 patients with PVT and no known risk factor for the development of PVT, in order 
to exclude cirrhosis or obliterative portal venopathy 15. Moreover, none of the patients classified as 
affected by portal hypertension secondary to PVT had a previous diagnosis of INCPH. 
Portal hypertension was attributed to idiopathic non-cirrhotic portal hypertension (INCPH) after 
having excluded cirrhosis by liver biopsy and portal and hepatic veins obstruction at Doppler 
Ultrasound and CT-scan. Other causes of liver disease (chronic viral hepatitis, alcoholic liver 
disease, non alcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis and Wilson disease) 
were also excluded by a complete diagnostic clinical and laboratory workout.  
Seventy-seven patients with cirrhosis due to HCV infection and belonging to Child-Pugh class A 
were enrolled as control. The diagnosis of liver cirrhosis was based on clinical, laboratory and 
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histological features. No cirrhotic patients received any direct acting antiviral drugs, which were not 
available during the study period. 
 
Patients initial evaluation and follow-up  
Data collection of each patient started at the moment of first observation. The initial manifestation 
leading to the diagnostic workout were upper gastrointestinal bleeding due to oesophageal varices 
in 32 patients, evidence of oesophageal varices at upper endoscopy in 22 patients, evidence of 
portal cavernoma or portosystemic collaterals in 23 patients and splenomegaly/hypersplenism in 12 
patients.  
All the patients were evaluated and followed by the same medical team. At the time of the first 
evaluation, a complete physical examination and routine serum analyses were performed in all 
patients; their detailed medical history was collected, and their symptoms and signs recorded. For 
the patients with INCPH and PVT the diagnostic work-up included a systematic screening for any 
underlying prothrombotic disorder due to hereditary thrombophilia (factor V Leiden mutation, 
prothrombin gene mutation, and inherited deficiencies for protein C, protein S and antithrombin and 
acquired hypercoagulability (i.e., myeloproliferative disorders, anti-cardiolipin antibodies, lupus 
anticoagulant antibodies). The screening for thrombophilia was carried out by a referral 
haematological centre. Since the study of inherited deficiencies in patients with chronic liver 
disorders is hard, in our study we considered only the patients with isolated protein C or S 
deficiency in which a familial study was after performed. Myeloproliferative diseases were 
screened by the detection of Janus tyrosine kinase-2 gene (JAK-2 V617F) mutation and confirmed 
by a bone marrow biopsy in all patients. Bone marrow biopsy was also performed in the patients 
without JAK2 V617F mutation but with phenotypic features strongly suggestive for a 
myeloproliferative disease. The patients affected by myeloproliferative neoplasm were regularly 
followed-up by a haematologist and treated with specific therapy when necessary.  
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All patients with PVT were submitted to oral anticoagulation targeting the INR between 2 and 3. 
Prophylactic anticoagulation was not proposed in the patients with INCPH or cirrhosis. 
An upper endoscopy was carried out in all the patients and oesophageal varices were graded and 
reported as small or large (medium and large varices were grouped together) 17,18. Longitudinal 
diameters of spleen and liver, portal vein diameter, portal vein thrombosis and presence of ascites 
were studied through Doppler-sonography and recorded. 
All patients were regularly followed up with clinical, laboratory and ultrasound evaluation every six 
months. In case of appearance of hepatic nodules at ultrasonography, the patients were submitted to 
a second level diagnostic work up for the diagnosis of hepatocellular carcinoma, which included the 
liver biopsy if necessary.  Endoscopic surveillance was made every 12 months, until the evidence of 
varices at risk of bleeding needing prophylaxis. All episodes of variceal bleeding, ascites or new 
thrombotic events occurring during the follow-up were recorded. The patients were followed for a 
mean of 8.4 ±15.3 years. 
The purpose of the study was clearly explained to all the patients before obtaining their written 
informed consent. The “Sapienza” University of Rome Ethical Committee approved the collection 
of data of the patients for prognostic studies (Rif.1720/01.10.09).  
 
Statistical analysis  
Data are expressed as mean ± SD, unless specified otherwise. Comparison between 2 groups 
was performed by chi square test or unpaired Student t test, when appropriate. Comparison between 
3 groups was performed by analysis of variance (ANOVA) and by Newman Keuls multiple 
comparison post hoc analysis. The occurrence of large varices, variceal bleeding, thrombosis, 
ascites as well as the cumulative survival rate was described by Kaplan-Meier plots. In order to test 
the independent correlation, adjusted for the other variables, between the diseases (cirrhosis vs 
non-cirrhotic portal hypertension) and each clinical outcome, we included the variables unequally 
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distributed (age, haemoglobin and disease) into a multivariate Cox Regression analysis. The 
Number Cruncher Statistical System (NCSS) was used for all computations. 
 
RESULTS 
Clinical presentation 
The clinical, biochemical and ultrasonographic features of the patients at entry are 
summarized in Table 1. Gender distribution was similar in the 3 groups, while age was significantly 
higher in patients with Child A cirrhosis compared to the other two groups. Bilirubin, ALT, albumin 
and cholinesterase were similar in the 3 groups while alkaline phosphatase was significant higher in 
patients with chronic PVT, likely due to the presence of hypertensive biliopathy in some patients. 
Platelets counts were also higher in the PVT group, likely due to presence of myeloproliferative 
diseases in 40% of the patients. Signs of portal hypertension (oesophageal varices, variceal 
bleeding, ascites, splenomegaly) were equally distributed in the three groups of patients. Spleen 
diameter was significant larger in patients with INCPH than in the other two groups. Portal vein 
diameter was larger in INCPH than in cirrhotic patients, while it was not measurable in the group of 
patients with chronic PVT. A portosystemic shunt was detected in 10 patients with non cirrhotic 
portal hypertension. The shunt was spleno-renal in 5 patients, gastro-renal in 4 and spleno-gastro-
renal in one patient). Presence and size of varices were determined at the time of the first 
observation of the patients. The number of patients with previous bleeding and therapeutic variceal 
banding was 10 in the Child A cirrhosis group, 3 in the INCPH group and 8 in the PVT group. The 
size of varices was similar in the 3 groups, as well the proportion of patients with previous variceal 
bleeding and previous endoscopic treatment at the first observation. The presence of ascites was 
also similar in the 3 groups.  
The presence of thrombophilic conditions was searched in the patients with non-cirrhotic portal 
hypertension only. A thrombophilia was found in 6 patients with INCPH (24%) and in 42 patients 
with chronic PVT (66%). The different kind of prothrombotic disorders is reported in Table 2. Four 
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patients with INCPH (16%) and 16 patients with PVT (25%) had at least one prothrombotic 
disorders while chronic myeloproliferative neoplasms were diagnosed in 2 patients with INCPH and 
in 26 patients with PVT.  
Moreover, other 8 patients were classified as having significant extrahepatic comorbidities or 
diseases known to be associated to INCPH. In particular 3 patients were treated with oxaliplatin 
chemotherapy for colorectal cancer, 3 patients were affected by common immune variable 
deficiency (CVID), one was affected by coeliac disease and one patient was HIV-positive.  
 
Clinical outcomes during follow-up 
Development of varices at risk of bleeding and incidence of variceal bleeding 
The development of large varices was studied only in the subgroup of patients and with no or small 
varices at first endoscopy and in patients without a history of previous variceal bleeding. In 3 
patients the first endoscopy was not available so they were not considered for variceal progression. 
In the 25 patients with INCPH, 11 had low risk varices (Absent=8; Small=3); in the 64 patients with 
PVT, 27 patients had low risk varices (Absent=15; Small=12). Finally, in the group of Child A 
cirrhosis (n=77), 40 patients had low risk varices (Absent=24; Small=16). None of these patients 
received drugs to reduce portal hypertension.  
Four patients with INCPH, thirteen with chronic PVT and twelve with compensated cirrhosis 
developed large varices during follow-up. The Kaplan-Maier curve showing the patients free of 
large varices during the follow up is reported in figure 1 in which, given the small number, the 
patients with INCPH and chronic PVT were pooled. The results are thus presented comparing the 
group of patients with Child A cirrhosis (n=40) with the group of patients with portal hypertension 
not due to cirrhosis (n= 38) and indicated in the figure as non-cirrhotic portal hypertension (NCPH). 
In the patients with non-cirrhotic portal hypertension, the rate of progression was more rapid than 
that observed in the patients with cirrhosis (p<0.0001, log rank test); (Figure 1), HR=5.6 (95% CI, 
2.2-14.1) at Cox multiple regression analysis. The difference between patients with cirrhotic and 
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NCPH remains significant also if the patients are stratified according to the variceal size at first 
endoscopy (with no varices or with small varices) as reported in Figure 2, Panel A and B.  
The incidence of first variceal bleeding during the follow-up was studied in the 109 patients without 
variceal bleeding at first observation.  
Of these 109 patients, 78 were without varices at risk of bleeding at the first observation. These 78 
patients were submitted to upper endoscopy every 12 months. The remaining 31 patients with 
varices at risk of bleeding were submitted to a treatment to prevent the first bleeding (primary 
prophylaxis) according to the guidelines for the management of portal hypertension in cirrhotic 
patients16, which included the use of non-selective beta-blockers (in 19 patients), carvedilol (in 5 
patients), and endoscopic banding  (in 5 patients). In the two remaining patients (both with INCPH), 
TIPS was performed in order to prevent the first variceal bleeding. These two patients had large 
varices not responding to band ligation and needed for oral anticoagulation because of the 
development of thrombosis. 
In patients with gastrointestinal bleeding upper endoscopy and US was performed immediately. 
Variceal haemorrhage occurred in four patients with INCPH, in 8 with chronic PVT and in 9 
patients with cirrhosis. As before, the patients with portal hypertension not due to cirrhosis were 
pooled. Variceal bleeding was lower in patients with Child A cirrhosis than in patients with non-
cirrhotic portal hypertension (p=0.02, log rank test) (Figure 3) HR=4.1 (95% CI, 1.5-10.8) at Cox 
multiple regression analysis. No other causes of bleeding were observed. 
A Doppler Ultrasound was routinely performed in all bleeding patients in order to check for the 
development of PVT. In no patients we found a relationship between thrombosis/re-thrombosis 
development and variceal bleeding. 
After bleeding, all the patients were submitted to secondary prophylaxis with the combination of 
band ligation and beta-blockers or TIPS according to the indication for the management of cirrhotic 
patients. TIPS was necessary for the prophylaxis of variceal rebleeding in 4 with INCPH, 3 patients 
with chronic PVT and only 1 patient with cirrhosis.  
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Portal vein thrombosis  
During the follow up, portal vein thrombosis occurred in eight patients with INCPH (32%) and in 
14 patients with Child A cirrhosis (18%); among the eight INCPH patients who developed portal 
vein thrombosis, six had a prothrombotic state and one was HIV positive. The incidence of portal 
vein thrombosis was significantly higher in patients with INCPH than in patients with compensated 
cirrhosis (p=0.02, log rank test) (Figure 4). A new thrombosis of the splanchnic area occurred in 13 
(20.3%) patients with chronic PVT. Among the thirteen patients with a new thrombotic event, in 
five oral anticoagulant therapy was temporarily stopped and temporarily shifted to LMWH because 
of the development of large varices with need of banding or because of variceal bleeding. 
Moreover, 6 patients had an underlying myeloproliferative neoplasm, which represented 23% of the 
patients with MPN. In these 6 patients a trend to higher gamma-GT levels than in those with MPN 
without re-thrombosis was observed (186±177 vs 68.5±61; p= 0.03). 
 
Ascites and survival 
During the follow up, ascites occurred in one INCPH patient, in four patients with PVT and in nine 
with cirrhosis class A Child-Pugh with an incidence rate higher in patients with cirrhosis than in 
patients with NCPH (p=0.004, log rank test) HR=0.08 (95% CI, 0.01-0.57) at Cox multiple 
regression analysis. None of the patients developed a hepatocellular carcinoma. 
During follow-up, 12 patients with cirrhosis and 5 patients with PVT died.  Only one patient with 
INCPH died during follow-up because of opportunistic encephalitis in HIV positive patient. No 
significant difference in survival was found between the three groups of patients (Figure 5). 
 
DISCUSSION 
Current recommendations on vascular liver disease 15-16 suggest to manage the patients with portal 
hypertension not due to cirrhosis according to the guidelines elaborated for cirrhotic patients. 
Accordingly, for example, the timing for the endoscopic surveillance should be the same of 
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cirrhotics. However, in cirrhotic patients this timing is based on the knowledge of the rate of 
progression of varices, which could be quite different in patients affected by a vascular liver 
disease. These “by analogy” recommendations are mainly due to the paucity of studies on the 
natural history of non cirrhotic portal hypertension in which a direct comparison of the main clinical 
outcomes occurring in patients with portal hypertension due or not due to cirrhosis 19, 20 is often 
lacking. This makes these recommendations at least arguable.  
To address this problem we reviewed the records of a group of patients with non-cirrhotic portal 
hypertension prospectively followed up according to a standardized protocol in our centre dedicated 
to the management of portal hypertension.    
The aim of our study was to determine the main presentation of non-cirrhotic portal hypertension 
and to describe the incidence of the most relevant clinical outcomes in comparison with those 
observed in a group of cirrhotic patients followed up according to the same protocol. For this aim 
all consecutive patients affected by chronic PVT or by INCPH were included. As control group, a 
cohort of Child-Pugh class A HCV positive cirrhotic patients was enrolled and followed up. The 
choice to include only patients with compensated cirrhosis due to HCV was made to have a control 
group with limited liver damage and with a natural history and disease progression more stable than 
that observable in other ethiology, such as alcohol.  
At diagnosis, there are no differences between patients with portal hypertension due to or not due to 
cirrhosis about signs of portal hypertension and liver function (Table 1). Compared to the other 
groups, the patients with INCPH had a spleen and portal vein diameter significantly higher than 
those of patients with cirrhosis. For the analysis of most clinical variables the patients with chronic 
PVT and INCPH were pooled in the group of non cirrhotic portal hypertension. 
In patients with non cirrhotic portal hypertension the rate of development of varices at risk of 
bleeding was significant higher than in patients with cirrhosis independently on the size of varices 
at the first endoscopy (Figure 1 and Figure 2, Panel A and B). This observation may at least 
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question the recommendation of repeating the endoscopy at the same time in patients with cirrhotic 
and non-cirrhotic portal hypertension. For example, according to the suggested guidelines for 
cirrhosis, a patient with no varices at the first endoscopy should be submitted to the next endoscopy 
after 2 or 3 years. However, at that time about 20% of the patients with NCPH already developed 
varices at risk (Figure 2, Panel A). The same occurs in patients with small varices at enrolment, in 
whom the next endoscopic control should be repeated one year later. Again, at that time, apparently, 
about 30% of the patients with NCPH already developed varices at risk. As the time of endoscopy 
defines the start of the prophylactic treatment, the recommendation to repeat endoscopy with the 
same schedule used in cirrhotic patients seems to be unjustified. The higher rate of variceal bleeding 
observed during the follow-up in patients with NCPH compared to cirrhosis, seems to further 
support the suggestion of a more rapidly progression of varices in this kind of patients.  
Another relevant difference between cirrhotic and non-cirrhotic patients is represented by the 
incidence of portal vein thrombosis, which is expectedly higher in the patients with chronic PVT. 
Our study confirm that the development of portal vein thrombosis is a common complication also of 
INCPH 21, 22,23 and suggests that it occurs more frequently than in patients with Child A cirrhosis.  
In 6 out of 8 INCPH patients in our series, it occurred in the presence of an underlying 
prothrombotic state 9, suggesting that in patients with INCPH, the slowdown in the flow of the 
portal vein is a necessary but not sufficient condition to allow the event to occur. This finding 
confirms the importance and the necessity to make a systematic screening for any underlying 
prothrombotic disorder in patients with INCPH and support to start anticoagulation at least in those 
with a prothrombotic state 12,24,25.  
However, being the gastrointestinal bleeding the main complication of INCPH and the role of 
thrombophilia in its pathogenesis still unclear, the generalized use of a potentially dangerous 
treatment such as anticoagulation remains uncertain, especially because a clear demonstration of the 
worsening of the natural history the disease after the development of a PVT is lacking. 
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Finally, we observed a recurrence of the splanchnic thrombosis in 13 patients with chronic PVT 
despite oral anticoagulation. Six of these 13 patients were affected by a MPN and 5 were 
temporarily shifted to LMWH because of variceal bleeding or progression needing endoscopic 
banding. This figure is similar to that reported in other series 25-26. This observation suggests to 
avoid unnecessary suspension of oral anticoagulation, in all patients and to optimize the treatment 
of the underlining disease in the patients with splanchnic thrombosis and MPN. Possible additional 
treatments in these latter patients are possible but never supported by evidences. Also of interest is 
the observation of higher Gamma-GT levels in the patients with MPN who developed a re-
thrombosis. Gamma-GT has been shown to be an independent biomarker of PVT in MPN patients 27 
without liver damage or portal hypertension. In patients with portal cavernoma, high gamma-GT 
may be related to portal biliopathy and/or the underlining liver damage.  More data are needed to 
establish if gamma-GT may be considered an independent biomarker of PVT also in this kind of 
patients, and if it may contribute to the identification of patients particularly prompt to this 
complication, eventually leading to changes in their management. 
However, the need to submit the patients with non cirrhotic portal hypertension to anticoagulation 
stress the importance of the endoscopic follow up in this kind of patients.  
Differently from the development of varices, the incidence of ascites is significantly lower in non 
cirrhotic patients while the overall survival resulted similar in patients with non cirrhotic portal 
hypertension and in patients with cirrhosis.  
In conclusion, more studies are needed to describe the natural history of patients with both INCPH 
and chronic PVT, with the aim of identifying clinically significant outcomes and the best 
management strategy. The infrequent occurrence of these diseases might heavily limit the 
possibility of carrying on randomized controlled trials. However, in these patients the use of the 
same strategies used for cirrhotic patients with portal hypertension may not be correct, both in terms 
of follow-up and treatments. The results of the present study, although obtained on a limited group 
of patients support the above conclusion. Cooperative multicentre studies, with an accurate patients’ 
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selection to limit their heterogeneity, are probably the best tool to attempt an answer to the many 
questions raised when dealing with such a complex disorders. 
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FIGURES LEGEND 
Figure 1. Incidence of progression to varices at risk of bleeding (cirrhosis vs non cirrhotic portal 
hypertension) 
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Figure 2. Progression to varices at risk of bleeding (cirrhosis vs non cirrhotic portal hypertension) 
in patients with no varices (panel A) and in patients with small varices (panel B) at first endoscopy 
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Figure 3. Incidence of variceal bleeding (cirrhosis vs non cirrhotic portal hypertension)  
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Figure 4. Incidence of portal vein thrombosis in patients with INCPH and in patients with cirrhosis 
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Figure 5. Cumulative survival (cirrhosis vs non cirrhotic portal hypertension)  
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Table 1: Characteristics of patients included in the study. 
 
Mean ± SD;   
* p<0.05 by ANOVA and Newman Keuls for the comparison between cirrhosis, INCPH and 
chronic portal vein thrombosis;   
# p<0.05 by student t test or X2 for the comparison between cirrhosis and grouped non-cirrhotic 
cohort 
 Child A 
Cirrhosis 
INCPH Chronic 
Portal vein 
thrombosis 
 
Grouped 
non-
cirrhotic 
cohort 
Patients (n) 77 25 64 89 
Age (mean  SD) 58.3±12.5* 45.04±17 
 
46±14 45.6±15.1# 
Sex (M/F) 47/30 17/8 30/34 47/42 
Bilirubin (mg/dl) 1.08±0.6 1.14±1.0 1.22±0.7 1.19 ± 0.82 
ALT (UI/l) 71±121 33.2±18.8 47±72 42.7 ± 61.3 
Alkaline 
phosphatase 
(UI/l) 
109±53 138±77 233±188* 202±166# 
ϒ-glutamyl 
transferase (UI/l) 
51.9±33.6 92.9±117 86±133 88.4±127.8 
Albumin (g/dl) 3.8±0.5 4.2±0.5* 3.9±0.6 4±0.6 
Cholinesterase 
(UI/l) 
7989±16466 7070±2517 5966±2255 6404±2403 
Hb (g/dl) 12.9±2.2 12.3±2.1 12.08±2.3 12.2±2.2# 
Platelet (x 103/μl) 111±95 100±73 290±240* 232±226# 
Esophageal 
Varices 
(absent/small/larg
e) 
24/22/30§ 
 
8/3/14 16/15/31§ 
 
24/18/45 
Previous Variceal 
bleeding 
(No/Yes) 
52(68%)/25(32%
) 
16(64%)/9(36%) 41(64%)/23(36%
) 
57 
(64%)/32(36%) 
Ascites (No/Yes) 61(79%)/16(21%
) 
20(80%)/5(20%) 50(78%)/14(22%
) 
70(79%)/19(21
%) 
Spleen Diameter 
(cm) 
14.6±2.9 17.5±5.7* 14.3±2.2 15.2±4.2 
Portal Vein 
Diameter (mm) 
12.5±2.3 14.8±2.8* ND  AC
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§ One patient in the cirrhosis group and 2 patients in the chronic PVT group were not submitted to 
endoscopy at entry because already submitted to variceal rebleeding prophylaxis when first 
observed; 
ND=not determined. 
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Table 2: Thrombophilic disorders observed in patients with portal hypertension not due to cirrhosis. 
 
             
 INCPH  
(25) 
Chronic 
Portal vein 
thrombosis 
(64) 
Thrombophilia (n of abnormalities) 
Factor V Leiden  
Prothrombin gene mutation 
Protein C or Protein S deficiency  
MTHFR mutation 
Anti-phospholipid antibodies   
Lupus anticoagulant antibodies  
 
1 
0 
0 
1 
0 
2 
 
 
1 
1 
8 
7 
8 
5 
Myeloproliferative neoplasms  
(n of patients) 
(Polycythemia Vera/ Essential 
Thrombocythemia/ Idiopathic myelofibrosis/ 
other) 
 
1/0/1/0 
 
 
 
 
5/7/10/4 
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